Carr Financial Group Corp Lowers Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Carr Financial Group Corp trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 37.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 750 shares of the medical research company’s stock after selling 450 shares during the period. Carr Financial Group Corp’s holdings in Thermo Fisher Scientific were worth $390,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in TMO. AQR Capital Management LLC lifted its stake in Thermo Fisher Scientific by 18.1% during the second quarter. AQR Capital Management LLC now owns 98,152 shares of the medical research company’s stock worth $54,278,000 after purchasing an additional 15,009 shares in the last quarter. Daymark Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 24.5% in the second quarter. Daymark Wealth Partners LLC now owns 619 shares of the medical research company’s stock valued at $342,000 after acquiring an additional 122 shares in the last quarter. MBB Public Markets I LLC raised its stake in shares of Thermo Fisher Scientific by 767.0% in the second quarter. MBB Public Markets I LLC now owns 29,278 shares of the medical research company’s stock valued at $16,191,000 after acquiring an additional 25,901 shares in the last quarter. Lummis Asset Management LP raised its stake in shares of Thermo Fisher Scientific by 1.2% in the second quarter. Lummis Asset Management LP now owns 3,030 shares of the medical research company’s stock valued at $1,676,000 after acquiring an additional 37 shares in the last quarter. Finally, Lighthouse Investment Partners LLC raised its stake in shares of Thermo Fisher Scientific by 91.3% in the second quarter. Lighthouse Investment Partners LLC now owns 10,892 shares of the medical research company’s stock valued at $6,023,000 after acquiring an additional 5,199 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,850 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,611,804.88. This trade represents a 4.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 44,850 shares of company stock worth $24,666,097 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $575.21 on Friday. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm has a market cap of $220.02 billion, a P/E ratio of 36.06, a P/E/G ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The business’s 50-day moving average price is $532.36 and its 200 day moving average price is $569.05.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm’s revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.69 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has initiated a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several analyst reports. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Evercore ISI cut their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. TD Cowen raised their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Finally, Redburn Atlantic started coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.